logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Apr 30, 2018

PharmaCyte Biotech Reports Successful Completion of Long-term Studies on Cells Used in Pancreatic Cancer Therapy

  • Apr 17, 2018

PharmaCyte Biotech Successfully Completes Multiple Course Ifosfamide Study

  • Apr 5, 2018

PharmaCyte’s Clinical Trial Cells Arrive Safely at Austrianova’s Encapsulation Facility

  • Apr 2, 2018

PharmaCyte Ships Clinical Trial Cells to Austrianova for Encapsulation

  • Mar 26, 2018

PharmaCyte Biotech Files Patent Applications to Broaden Protection of Cancer Therapy in U.S. and Worldwide

  • Feb 28, 2018

PharmaCyte Discusses Phase 2b Clinical Trial in Pancreatic Cancer

  • Feb 26, 2018

PharmaCyte Announces Successful Completion of 6-Month Stability Study on Encapsulated Cells for Clinical Trial

  • Feb 6, 2018

PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank

  • Jan 10, 2018

PharmaCyte Announces Completion of Master Cell Bank

  • Dec 11, 2017

PharmaCyte Biotech Meets with Oncology Advisory Board

RSS
  • « Previous
  • 1...
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • ...30
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease May 21, 2024
  • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. November 15, 2023